Prostacyclins have established efficacy in pulmonary arterial hypertension, but their use has
not been described in LAM patients. Our case series highlights that prostacyclin analogs can …

Background Primary pulmonary hypertension (PPH) is a progressive disease with a median
survival of less than 3 years from diagnosis. Medical management has typically consisted of …

Prostacyclin treatment successfully delays the need for lung transplantation in many patients
with progressive primary pulmonary hypertension by vasodilating pulmonary arteries …

Advances in medical therapy and transplantation have improved the prognosis for patients
with primary pulmonary hypertension (PPH). Calcium channel blocking agents are …

Over the last decade, new medical and surgical treatments have become available for
primary pulmonary hypertension that have influenced the natural history of the disease …

The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical
response is scarce except for lung transplantation when prostacyclin infusion is ineffective …

We report our experience with two patients diagnosed of primary pulmonary hypertension
who later received lung transplants, with treatment with short-acting pulmonary vasodilators …

Objectives: The aim of this study was to evaluate the long-term effects of living-donor lobar
lung transplantation (LDLLT) for critically ill patients with pulmonary arterial hypertension …

Primary pulmonary hypertension (PPH) continues to be a major problem. Vasodilator
therapy has been of variable success in selected patients. Recently, with the introduction of …

Background Accepted treatment for severe pulmonary arterial hypertension (PAH) includes
intravenous epoprostenol and lung transplantation (LT). Inhaled iloprost plus oral sildenafil …